Frontlight ResearchEarly access
Active, not recruitingNo phase
Immune Resolution After Staphylococcus Aureus Bacteremia
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 102 people enrolled
- Started
- Jun 2013
- Expected to end
- Jun 2027
- Type of study
- Observational, 2 groups
- Record updated
- 13 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- At least one blood culture positive for S. aureus
- Patients aged ≥18 years
- At least two of four systemic inflammatory response syndrome (SIRS) criteria on the day of positive blood cultures. SIRS criteria are:; Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F); Heart rate greater than 90 beats per minute; Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or, an arterial partial pressure of carbon dioxide less than 32 mmHg; WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³ (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils (band forms)
Who cannot take part
- Sequential Organ Failure Assessment (SOFA) score > 12 on day of positive blood cultures
- Survival expected to be < 7 days from positive blood cultures
Where in United States
- University of Chicago HospitalChicago, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.
Read full original descriptionShow less
We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.
The 2 groups in the trial
- Immunosuppressed
Immunosuppressed includes patients with any one of the following: 1. a diagnosis of a hematological malignancy 2. a diagnosis of HIV 3. myelosuppressive chemotherapy in the previous 90 days 4. immune-modulating medications in the previous 90 days
- Non-Immunosuppressed
Subject does not fit immunosuppressed criteria
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 July 2026